This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Comment: Pfizer-Seagen clearance, Sanofi-Maze challenge show US FTC carefully selecting theories of harm in pharma sector

By Flavia Fortes and Serafina Smith ( December 13, 2023, 18:35 GMT | Comment) -- The US Federal Trade Commission’s decision not to challenge Pfizer’s proposed $43 billion acquisition of Seagen, but to file a lawsuit seeking to block Sanofi’s licensing deal with Maze, shows that the agency is carefully selecting which theories of harm it can push forward in the pharmaceutical sector.The US Federal Trade Commission’s decision not to challenge Pfizer’s proposed $43 billion acquisition of Seagen, but to file a lawsuit seeking to block Sanofi’s licensing deal with Maze, shows that the agency is carefully selecting which theories of harm it can push forward in the pharmaceutical sector....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login